Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Phase II Study To Evaluate The Efficacy And Safety Of ABSK021 In Combination With Chemotherapy With Or Without Toripalimab In Patients With Advanced Pancreatic Cancer

Next Previous
Trial Profile

A Multicenter, Open-Label Phase II Study To Evaluate The Efficacy And Safety Of ABSK021 In Combination With Chemotherapy With Or Without Toripalimab In Patients With Advanced Pancreatic Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Pimicotinib (Primary) ; Toripalimab (Primary)
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Abbisko Therapeutics

Most Recent Events

  • 18 Sep 2024 According to Abbisko Therapeutics media release, design of this trial was presented at the Hepatocellular Carcinoma poster session ESMO2024
  • 04 Dec 2023 According to a Merck KGaA media release, the company obtained approval from NMPA to initiate this trial.
  • 03 Nov 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top